SNSS Sunesis Pharmaceuticals Inc.

0.87
+0.04  (+5%)
Previous Close 0.83
Open 0.81
Price To Book 21.76
Market Cap 96,881,796
Shares 111,320,000
Volume 204,352
Short Ratio
Av. Daily Volume 680,123

NewsSee all news

  1. Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto

  2. Sunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Finance and Corporate

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 next update due at ASH December 2019. Noted 300 mg Cohort is now enrolling - July 8, 2019.
Vecabrutinib (SNS-062)
Advanced B-Cell Malignancies
Phase 2 investigator sponosored trial initiated March 2016
Vosaroxin in combination with cytarabine - VITAL
Previously untreated acute myeloid leukemia (AML) cancer
Phase 2 updated data released June 2016
Vosaroxin in combination with decitabine
Older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) - cancer
Endpoint not met Oct 2014. Additional trials required.
Voreloxin
Cancer - Acute myeloid leukemia AML

Latest News

  1. Sunesis Pharmaceuticals Appoints Dr. Nicole Onetto to the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto

  2. Sunesis Pharmaceuticals to Present at the Wells Fargo Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Finance and Corporate